Lung function and asthma control with beclomethasone and formoterol in a single inhaler  by Huchon, G. et al.
Respiratory Medicine (2009) 103, 41e49ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedLung function and asthma control with
beclomethasone and formoterol in a single inhalerG. Huchon a, H. Magnussen b, A. Chuchalin c, L. Dymek d, F. Bonnet Gonod e,
J. Bousquet f,*,ga Service de Pneumologie et Re´animation, Hoˆpital de l’Hoˆtel-Dieu, Paris, 1 Place du Parvis Notre Dame, 75181,
Cedex 04, France
b Hospital Grosshansdorf, Centre for Pneumology and Thoracic Surgery, Woehrendamm 80, 22927 Grosshansdorf, Germany
c Scientific Research Institute for Pulmonology, Russian State Medical University, 11 Parkovaya Street, 32/61 105077,
Moscow, Russia
d Centrum Medyczne Lucyna Andrzej Dymek, Strzelce Opolskie, Parafialna 1, 47100, Poland
e Chiesi Farmaceutici SpA, Via Palermo 26/A, 43100 Parma, Italy
f Clinique des Maladies Respiratoires, Hoˆpital Arnaud de Villeneuve, Centre Hospitalier Universitaire, 34295 Montpellier
Cedex 5, France
Received 22 July 2008; accepted 1 September 2008
Available online 1 November 2008KEYWORDS
Corticosteroid;
Airway inflammation;
Long-acting b2 agonist;
Hydrofluoroalkane;
Combination therapy;
Extra-fineList of abbreviations: ACTH, adrenoc
carbon; DPI, dry powder inhaler; ECG
expiratory volume in one second; FVC
treat; LSM, least squares mean; MDI,
protocol; SD, standard deviation; SE,
* Corresponding author. Tel.: þ33 46
E-mail address: jean.bousquet@in
g Member of GA2LEN, supported by
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.09.002Summary
Background: Lung deposition is crucial for asthma treatment. However, there is no study
comparing the potential role of lung co-deposition of combination therapy (inhaled corticoste-
roid and long-acting b2 agonist) in the same inhaler. In moderate to severe asthmatics, an
extra-fine hydrofluoroalkane combination of beclomethasone dipropionate and formoterol
given via a single pressurised metered-dose inhaler (pMDI) was compared with beclomethasone
dipropionate chlorofluorocarbon (CFC) pMDI and formoterol dry powder inhaler (DPI) given via
separate inhalers.
Methods: In a double-blind, double-dummy, 24-week randomised clinical trial, 645 patients
with moderate to severe asthma uncontrolled by regular treatment with inhaled corticoste-
roids received regular treatment with extra-fine fixed combination beclomethasone dipropio-
nate 200 mg/formoterol 12 mg bid, or beclomethasone dipropionate (500 mg bid) via CFC pMDI
and formoterol (12 mg bid) via DPI, or beclomethasone dipropionate (500 mg bid) via CFC pMDI.orticotropic hormone; ANCOVA, analysis of covariance; CI, confidence interval; CFC, chlorofluoro-
, electrocardiogram; FEF25e75%, forced expiratory flow between 25% and 75% of FVC; FEV1, forced
, forced vital capacity; GINA, global initiative for asthma; HFA, hydrofluoroalkane; ITT, intention to
metered-dose inhaler; PEF, peak expiratory flow; pMDI, pressurised metered-dose inhaler; PP, per
standard error.
7 33 61 05; fax: þ33 467 04 27 08.
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42 G. Huchon et al.The primary outcome was morning peak expiratory flow (PEF). Secondary outcomes included
lung function measured at clinic, asthma symptoms and control, exacerbations.
Results: Beclomethasone dipropionate/formoterol combination via single inhaler or via sepa-
rate inhalers improved morning PEF. However, the combination via single inhaler was more
effective than given via separate inhalers for asthma control. Both combination treatments
were superior to beclomethasone dipropionate alone in improving lung function and asthma
control. All treatments were well tolerated.
Interpretation: In patients with moderate to severe asthma, beclomethasone dipropionate/
formoterol in a single inhaler was as effective as beclomethasone dipropionate plus formoterol
and superior to beclomethasone dipropionate alone in improving lung function. For the first
time with a single inhaler, beclomethasone dipropionate/formoterol was significantly superior
to separate components for asthma control. This trial is registered with ClinicalTrials.gov,
number NCT00476268.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Asthma is a global health problem and patients with
moderate to severe disease need optimal treatment to
avoid severe exacerbations. All guidelines recommend
combination therapy using an inhaled corticosteroid plus
a long-acting b2 agonist for patients insufficiently
controlled by inhaled corticosteroids alone.1,2 Three pre-
parations are commercially available: fluticasone propio-
nate with salmeterol, or budesonide with formoterol or
beclomethasone dipropionate with formoterol. The latter
combination is formulated as a hydrofluoroalkane-134a
(HFA-134a)-containing pressurised metered-dose inhaler
(pMDI), developed using the Modulite solution formulation
technology.3 It delivers extra-fine particles of 100 mg
beclomethasone dipropionate and 6 mg formoterol4 per
actuation which are suitable for high lung deposition and
homogeneous distribution throughout the lung.5 In
moderate to severe asthmatic patients, it was found to
have a comparable efficacy to the two other fixed-dose
combinations.6,7
Lung deposition is crucial for an optimal treatment of
asthma. Inflammation of the small airways (internal diam-
eter <2 mm) is an important feature of asthma and treat-
ment of distal lung inflammation may be key for
appropriate asthma pharmacotherapy.8 Hydrofluoroalkane
propelled metered-dose inhalers deliver fine particles
which may target the lower airways. However, there is no
study showing that the co-deposition via single inhaler of
a corticosteroid and a long-acting b2 agonist in the distal
lung improves the control of asthma better than the same
drugs deposited via separate inhalers.
It was shown that the dose of 100 mg of beclomethasone
dipropionate in the extra-fine formulation delivers a fine
particle dose comparable to a 250 mg dose of beclometha-
sone dipropionate via a CFC-containing pMDI (ratio of
1:2.5).4 Moreover, in adults with moderate asthma, beclo-
methasone dipropionate extra-fine HFA pMDI was clinically
equivalent (peak expiratory flow rate), to beclomethasone
dipropionate via a CFC-containing pMDI at a dose ratio of
1:2.5.9,10
This paper describes a multi-centre, multinational Phase
III, double-blind, double-dummy, clinical trial designed to
establish that this HFA extra-fine beclomethasonedipropionate 100 mg with formoterol 6 mg fixed combination
is clinically non-inferior to CFC-beclomethasone dipropio-
nate 250 mg and formoterol 6 mg administered via separate
inhalers, and superior to CFC-beclomethasone dipropionate
250 mg alone, in patients eligible for inhaled corticosteroid/
long-acting b2 agonist combination therapy according to
current guidelines.1,2
Methods
Participants
This study recruited men and non-pregnant women (18e70
years), with a diagnosis of moderate to severe persistent
asthma according to GINA 2005,11 a forced expiratory
volume in one second (FEV1) ranging from 40% to 80% pre-
dicted values, and a positive reversibility test after salbu-
tamol performed within the two years before screening
(FEV1 increase in FEV1 over 12% baseline value and at least
200 ml).12 Participants had received at least two-month
treatment with CFC-beclomethasone dipropionate 750e
1000 mg, or equivalent either alone or associated with
a long-acting b2 agonist (formoterol 24 mg or salmeterol
100 mg per day), plus daily use of a short-acting beta-
agonist. Asthma symptoms occurred over three times
during the week before study entry.
Patients were excluded if they had smoked at least 20
cigarettes per day for ten years. The study recruited
outpatients at 104 centres in Belgium (1), France (15),
Hungary (5), Poland (15), Romania (14) and Russia (54).
Treatments
Participants were enrolled in a two-week run-in and
continued their previous asthma treatments. If eligibility
criteria were confirmed, participants were randomised to
receive one of three treatments:
(1) pMDI containing beclomethasone dipropionate 100 mg
and formoterol 6 mg per inhalation, with HFA-134a as
a propellant (Foster; Chiesi Farmaceutici).
(2) CFC pMDI containing beclomethasone dipropionate
250 mg per inhalation (Becloforte; Allen & Hanburys),
Beclomethasone and formoterol single inhaler in asthma 43plus a DPI containing formoterol 12 mg per capsule
(Foradil Aerolizer; Novartis).
(3) CFC pMDI containing beclomethasone dipropionate
250 mg per inhalation (Becloforte).
Each participant received three inhalers (containing
active drug or placebo) to maintain blinding while using
inhalers of different appearance. Patients were instructed
to take their assigned study drug (plus alternative placebos)
twice daily at 8.00 am and 8.00 pm as follows:
(1) two puffs beclomethasone dipropionate/formoterol
(400 mg/24 mg per day), plus a placebo equivalent to
one capsule formoterol DPI Aerolizer and a placebo
equivalent to two puffs beclomethasone dipropionate
CFC pMDI.
(2) two puffs beclomethasone dipropionate CFC (1000 mg
per day) plus one capsule formoterol DPI Aerolizer
(24 mg per day), plus a placebo equivalent to two puffs
Foster via pMDI.
(3) two puffs beclomethasone dipropionate CFC (1000 mg
per day), plus a placebo equivalent to one capsule
formoterol DPI Aerolizer and a placebo equivalent to
two puffs Foster via pMDI.
Randomisation
Randomisation was performed according to a balanced
block design with a centrally generated randomisation
code. Blocks of three randomisation numbers were allo-
cated to each centre.
Objectives
The primary objectives of this study were to demonstrate
that a fixed-dose combination of beclomethasone dipropi-
onate and formoterol was non-inferior to beclomethasone
dipropionate and formoterol given separately, and superior
to beclomethasone dipropionate alone, over 24 weeks in
adults with moderate to severe persistent asthma.
Efficacy outcomes
Mean morning peak expiratory flow (PEF) measured by the
patient before dosing during the last 14 days of treatment
was the primary efficacy endpoint. Baseline morning PEF
was the mean of all values recorded during the run-in
period. Patients recorded their PEF with an electronic peak
flow meter (Spirotel, MIR, Italy).
Secondary efficacy endpoints included evening PEF, daily
PEF variability, morning and evening FEV1, day and night
asthma symptom scores (cough, wheezing, chest tightness,
breathlessness and attack) on a four-point scale where
0Z none, 1Zmild, 2Zmoderate and 3Z severe, and sal-
butamol use. The percentage of days and/or nights without
clinical symptoms and days with asthma controle defined as
no or minimal clinical symptoms, no asthma-related
unscheduled medical visits, less than three puffs/day SABA,
no limitation on activities, daily PEF variability 20% and no
drug-related adverse events (AEs) (GINA 2004) e was evalu-
ated. Additionally, a post-hoc analysis was performed byassessing asthma control as: no nocturnal awakenings, no
asthma symptoms and no rescue medication used.13
Spirometry was performed at each clinic visit (screening,
baseline and after two, four, eight, 16 and 24-week treat-
ment), and lung function tests (FEV1, PEF, forced vital
capacity [FVC] and forced expiratory flow between 25% and
75% of FVC [FEF25e75%]) were measured.
The occurrence of asthma exacerbations was recorded,
according to pre-defined criteria, as follows:
Mild-to-moderate exacerbation: diurnal PEF variability
>20% and 30%; SABA use between four and eight puffs per
day; or nocturnal awakening due to asthma e all during at
least two consecutive days.
Severe exacerbation: need for oral corticosteroid;
asthma-related unscheduled medical visit or visit to an
emergency department; hospital admission for asthma;
diurnal PEF variability >30% or SABA inhalation of more
than eight puffs per day during at least two consecutive
days; or nocturnal awakening due to asthma during at least
three consecutive 24-hour periods.
Safety outcomes
Adverse events were assessed by investigators at clinic
visits and recorded by patients on paper diary cards. Vital
signs, ECG (including QTc interval) and haematology/blood
chemistry were evaluated during the treatment.
Morning serum cortisol (with adrenocorticotropic
hormone [ACTH] stimulation test)14 and overnight (12-hour)
urinary cortisol/creatinine ratios were also measured at
baseline and at week 24 in a subgroup of 93 patients.
Statistical methods and sample size
Efficacy data were analysed for both the intention to
treat (ITT) and per-protocol (PP) populations. The ITT
population included all participants who received at least
one inhalation of study drug and had at least one post-
baseline efficacy evaluation. Participants in the ITT
population without major protocol deviations formed the
PP population. The safety population included all
patients who received at least one inhalation of study
drug. The last available post-baseline values were carried
forward to the end of treatment time point for missing
data.
The non-inferiority of beclomethasone dipropionate/
formoterol fixed combination versus beclomethasone
dipropionate plus formoterol free combination, and its
superiority versus beclomethasone dipropionate mono-
therapy, for morning pre-dose PEF (measured on the Spi-
rotel) and clinic FEV1 were tested using an analysis of
covariance (ANCOVA) model, including terms for treatment
and centre as main effects and baseline value as
covariates.
A sample size of nZ 191 patients per group assured 80%
power for the non-inferiority test of beclomethasone
dipropionate/formoterol versus beclomethasone dipropio-
nate plus formoterol, assuming an estimated difference on
morning PEF (l/min) between beclomethasone dipropio-
nate/formoterol versus beclomethasone dipropionate plus
formoterol equal to zero, with a standard deviation of
morning PEF equal to 60 l/min and a non-inferiority margin
44 G. Huchon et al.fixed at 20 l/min. This sample size also provided more than
80% power to detect a clinically relevant difference (that
is, larger than the non-inferiority margin) for the test of
superiority of beclomethasone dipropionate/formoterol
over beclomethasone dipropionate alone.
All secondary endpoint data were summarised and ana-
lysed for both ITT and PP populations. Continuous endpoints
(evening PEF, daily PEF variability, morning and evening
FEV1, clinic-measured lung function tests, percentage of
nights/days/complete days free of asthma symptoms,
mean number of asthma exacerbations per patient, daily
salbutamol use and percentage of days asthma was
controlled) were summarised by treatment group and visit
or period as appropriate, with analysis and presentation of
results as for the primary efficacy endpoint. Morning and
evening asthma clinical symptom scores were treated as
continuous endpoints.
For the primary efficacy variable all the comparisons had
to show statistical significance at the required level,
therefore no formal adjustment for multiple comparisons
was needed. For the secondary efficacy variables the
adjustment was not considered necessary being these used
for supportive purpose only.
Results
Participants
Atotal of 824patientswere screenedand645wererandomised
to treatment, of whom 596 (92.4%) completed the 24-week
study. The first patient entered the study on 7 February 2004
and the last patient completed the study on 28 January 2005.
Patient disposition is shown in Fig. 1. Baseline charac-
teristics were similar between groups, as shown in Table 1.
Lung function
The primary outcome of the study, namely morning PEF, was
significantly higher compared with baseline for both beclo-
methasone dipropionate/formoterol fixed combination andFigure 1 Patient disposition. BDP: beclomethabeclomethasone dipropionate plus formoterol free combi-
nation, but remained unchanged for beclomethasone
dipropionate monotherapy (Fig. 2). Results in the ITT and PP
populations were similar.
At the end of the treatment, non-inferiority of the fixed
versus the free combination, and superiority versus beclo-
methasone dipropionate alone, were shown in both the ITT
and PP populations. Analyses are presented in Table 2. FEV1
measured at clinics confirmed the non-inferiority of the
fixed versus the free combination and its superiority to
beclomethasone dipropionate alone in both the ITT and PP
populations (Table 2; Webfigure 1).
Results of other lung function variables (namely FVC and
FEF25e75) were consistent with the primary endpoint in both
the ITT and PP populations (results for the ITT population
are presented in Webtable1).
Asthma control measures
During the 24 weeks of the study, the percentage of days
and/or nights and/or complete days free of asthma
symptoms, and percentage of days with asthma control
were unchanged on beclomethasone dipropionate alone,
but increased from baseline on both the fixed and free
combinations. Moreover, values at the end of the study
were significantly higher in the fixed combination group
than in the free combination (p< 0.05) or beclomethasone
dipropionate monotherapy (p< 0.01) groups (Webfigure 2).
A post-hoc analysis confirmed a significantly higher
percentage of days with asthma control in the fixed
combination group than in the free combination
(p< 0.005) or beclomethasone dipropionate monotherapy
(p< 0.0001) groups (Webtable 2 and Fig. 3). Accordingly,
salbutamol use fell significantly from baseline to end of
treatment in both combination groups (mean differences
from baseline: 0.29, 95% CI [0.44, 0.14] and 0.36,
95% CI [0.52, 0.19] puffs/day, for fixed and free
combination, respectively). There was no change from
baseline in the beclomethasone dipropionate monotherapy
group.sone dipropionate; FF: formoterol fumarate.
Table 1 Baseline patient characteristics
BDP/formoterol
fixed combination
BDPþ formoterol
free combination
BDP monotherapy
n (randomised) 212 220 213
Female/male [% female] 138/74 [65.1] 143/77 [65.0] 134/79 [62.9]
Mean age (years) SD 47.3 12.31 47.4 12.20 47.3 13.05
Mean height (cm) SD 167.11 8.822 166.97 8.336 167.28 8.548
Mean weight (kg) SD 74.41 14.425 75.54 15.451 74.87 14.943
Morning PEF (l/min) SD 318.37 109.29 310.26 98.97 303.52 105.73
FEV1 (l) SD 1.95 0.53 1.99 0.56 1.97 0.56
Mean FEV1 (% predicted) SD 64.5 10.79 66.2 10.99 65.3 10.64
Smoking history (n) [%]
Never smoked 172 [81.1] 183 [83.2] 167 [78.4]
Former user 28 [13.2] 24 [10.9] 38 [17.8]
Smoker 12 [5.7] 13 [5.9] 8 [3.8]
Patients on inhaled corticosteroid/long-acting
b2 agonist at entry (n)
104 104 102
Mean inhaled corticosteroid
dose at entry (mg) SDa
658.79 196.3 666.23 215.1 681.45 226.97
Daily SABA use (puffs/day) SD 0.65 1.11 0.74 1.40 0.57 1.20
Days free of asthma symptoms (%) SD 21.2 27.8 21.9 28.1 25.6 30.5
Nights free of asthma symptoms (%) SD 23.7 29.9 26.9 30.8 27.3 31.9
Complete days free of asthma symptoms (%) SD 10.8 21.2 11.9 20.3 14.8 24.4
BDP: beclomethasone dipropionate; FEV1: forced expiratory volume in one second; FF: formoterol fumarate; ICS: inhaled corticosteroid;
LABA: long-acting beta-agonist; PEF: peak expiratory flow; SABA: short-acting beta-agonist; SD: standard deviation.
a Mean of daily inhaled corticosteroid dose, irrespective of the type of inhaled corticosteroid.
Figure 2 Morning peak expiratory flow rate (l/min) in ITT
population. BDP: beclomethasone dipropionate; FF: formoterol
fumarate; PEF: peak expiratory flow rate; ITT: intention to
treat.
Beclomethasone and formoterol single inhaler in asthma 45A total of 280, 351 and 428 asthma exacerbations were
reported in the beclomethasone dipropionate/formoterol
fixed combination, beclomethasone dipropionate plus for-
moterol free combination and beclomethasone dipropio-
nate monotherapy groups, respectively. Of these, 96, 145
and 160, respectively, were classified as severe. A post-hoc
analysis showed that the number of events per patient was
significantly lower (p< 0.05) on fixed combination
compared with beclomethasone dipropionate mono-
therapy, and non-significant differences were observed
versus the free combination (Table 3, Fig. 4). In particular,
the overall number of exacerbations per patients was
reduced by 35% with beclomethasone dipropionate/for-
moterol fixed combination versus BDP monotherapy.
A minority of patients (3 subjects receiving the fixed
combination, 8 on free combination and 9 with beclome-
thasone dipropionate alone) experienced exacerbations
that required oral corticosteroid treatment.
Tolerability and safety outcomes
Similar numbers of patients reported treatment-related
adverse events in each group (Webtable 3). The majority of
treatment-related adverse events was mild in intensity and
only very few patients were withdrawn due to adverse
events (Fig. 1).
In the beclomethasone dipropionate plus formoterol
free combination and beclomethasone dipropionate mon-
otherapy groups, the analysis of morning serum cortisol
levels and overnight urinary cortisol/creatinine ratios did
not show any significant inhibition of adrenal function after24 weeks of treatment compared with baseline.
Conversely, a significant increase versus baseline (p< 0.05)
in cortisol levels, which, however, has remained within the
normal range, was observed in patients in the beclome-
thasone dipropionate/formoterol fixed combination group
(Fig. 5). There were no patients with normal cortisol levels
at baseline showing a decrease below normal range in the
fixed combination group, while three patients in both the
free combination and beclomethasone dipropionate mon-
otherapy groups had a decrease of cortisol levels from
Figure 3 Percentage of days with asthma control in beclo-
methasone dipropionate/formoterol fixed combination,
beclomethasone dipropionate plus formoterol free combina-
tion and beclomethasone dipropionate monotherapy groups
(ITT population; post-hoc analysis). BDP: beclomethasone
dipropionate; FF: formoterol fumarate; ITT: intention to treat.
Asthma control was defined according to Zetterstrom et al.13
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46 G. Huchon et al.normal to below normal range. The ACTH stimulation test
confirmed the lower inhibitory effect of the fixed combi-
nation on the hypothalamic-pituitary-adrenal axis, as the
number of responders increased from baseline, while
decreasing in both the comparator groups.
There was no variation over time of blood haematology
and biochemistry results or ECG. Systolic and diastolic
blood pressure (BP) and heart rate (HR) did not change over
time.
Discussion
This study demonstrates that beclomethasone dipropio-
nate/formoterol fixed combination is non-inferior to
beclomethasone dipropionate and formoterol given via
separate inhalers, and superior to beclomethasone dipro-
pionate given alone, for the primary endpoint, morning
PEF. Results were consistent in both the ITT and PP pop-
ulations. As for asthma control, the fixed combination was
superior to the two components given separately.
Randomised controlled studies of the two existing
fixed-dose inhaled corticosteroid/long-acting b2 agonist
combinations (budesonide/formoterol and fluticasone
propionate/salmeterol) have demonstrated equivalence
or non-inferiority to an inhaled corticosteroid plus a long-
acting b2 agonist via separate inhalers, but failed to show
any advantage over the equivalent combination of the
separate components.13,15e18
The primary goal of the present study was to show that
an extra-fine pMDI solution of a fixed combination of
beclomethasone dipropionate/formoterol was non-inferior
to the reference formulations of beclomethasone dipropi-
onate and formoterol given via separate inhalers in
improving lung function of patients with moderate to
severe persistent asthma. This was confirmed for the
Table 3 Comparison between treatments for Asthma Exacerbations per patient
BDP/formoterol
fixed combination
(nZ 211)
BDPþ formoterol
free combination
(nZ 220)
p value BDP/formoterol
fixed combination
(nZ 211)
BDP monotherapy
(nZ 212)
p value
Overall exacerbationsa 1.3 (1.92) 1.6 (2.34) 0.187 1.3 (1.92) 2.0 (2.69) 0.001
Mild-moderate exacerbationsa 0.9 (1.37) 0.9 (1.69) 0.600 0.9 (1.37) 1.2 (2.29) 0.022
Severe exacerbationsa 0.5 (0.98) 0.7 (1.30) 0.103 0.5 (0.98) 0.8 (1.48) 0.030
Statistical analysis performed by means of an ANCOVA model; BDP: beclomethasone dipropionate.
a Mean number of exacerbations per patient (SD). Evaluation performed on the intention to treat population.
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Figure 4 Overall asthma exacerbations per patient during
the study (ITT population; post-hoc analysis). BDP: beclome-
thasone dipropionate; FF: formoterol fumarate; ITT: intention
to treat.
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as FEV1, FVC and FEF25e75%. These results are consistent
with previous observations of other fixed combinations of
a long-acting b2 agonist plus an inhaled corticosteroid.17
Although the minimum dose required to achieve asthma
control was not established in this study, previous rando-
mised controlled trials confirmed the comparable efficacy
and safety of beclomethasone dipropionate extra-fine HFA
400 mg and non extra-fine CFC 1000 mg daily.9,10,19e21
In this study different formulations of beclomethasone
dipropionate and formoterol in a single inhaler versus the
separate components were compared due to the limited
market availability of extra-fine beclomethasone dipropio-
nate HFA 100 mg pMDI and extra-fine formoterol 12 mg HFA
pMDI at that time (2004e2005) and in the countries where
the trial was carried out, as well as to technical difficulties
in producing adequate dummy placebos.
However, the clinical validity of that result is assured by
the fact that randomised clinical studies with the single
components of beclomethasone/formoterol single inhaler
had shown a similar efficacy in pulmonary function
improvement between extra-fine beclomethasone HFA and
CFC beclomethasone at 1:2.5 dose ratio,9 as well as
between extra-fine formoterol HFA pMDI and formoterol DPI
Aerolizer at equivalent doses.4 Indeed, in agreement with
these findings, the present investigation confirmed that
beclomethasone/formoterol fixed combination is able to
provide lung function improvement comparable to the
separate components.
In the present study, it was also observed that treatment
with beclomethasone dipropionate/formoterol fixed
combination was associated with significantly higher
percentages of controlled days and nights and a better
asthma control score than the administration of the two
drugs separately or beclomethasone dipropionate alone.
This is important because the control of asthma is the main
therapeutic goal of asthma guidelines.22 The control of
asthma can be assessed using several methods and control
questionnaires can be used.22e24 We followed the method
of Zetterstrom et al.13 since it is found to be one of the
most stringent ones and has been published in a randomised
control trial. Furthermore, the beclomethasone dipropio-
nate/formoterol treatment group experienced fewer
overall and severe exacerbations than the free combination
or beclomethasone dipropionate monotherapy groups,
although only the comparison between beclomethasone
dipropionate/formoterol fixed combination and beclome-
thasone dipropionate alone reached statistical significance
(post-hoc analysis).A meta-analysis indicated that the fluticasone propio-
nate plus salmeterol combination offers the potential for
increased clinical efficacy on PEF over concurrent use of
the same doses of the two drugs.25 However, this is the first
observation in a randomised controlled trial of a difference
in asthma control between an inhaled corticosteroid and
a long-acting b2 agonist given as a fixed combination and
via separate inhalers. The statistical relevance of this
finding could be discussed since we used multiple compar-
isons, but, even using Bonferroni’s correction, the results
would still be significant for the control of asthma. This
finding could be related to the lung deposition profile of
beclomethasone/formoterol extra-fine formulation, which
allows a distribution of the two drugs both in central and
small airways.5 Interestingly, in vitro, the two extra-fine
components of beclomethasone dipropionate and for-
moterol in the combination investigated in this study show
a comparable particle size distribution with the same fine
particle fraction, suggesting in vivo potential for co-depo-
sition throughout the entire bronchial tree.26 The present
study suggests that the synergistic effect of the two drug
classes at various cellular types in the lungs27 can be
enhanced through their co-administration and consequent
Figure 5 Change from baseline in mean morning serum
cortisol (nmol/l). BDP: beclomethasone dipropionate; FF: for-
moterol fumarate.
48 G. Huchon et al.co-deposition,25 which might be favoured by the extra-fine
formulation of the beclomethasone/formoterol combina-
tion. This could also explain the reason why such a differ-
ence in asthma control versus non-extra-fine combinations
has been shown only when formoterol extra-fine is
combined with an extra-fine corticosteroid in a single
inhaler and not when administered alone.28
A well-established property of inhaled corticosteroid
extra-fine formulations is the possibility of administering
a lower nominal dose of corticosteroid, while maintaining
the same clinical efficacy of their reference CFC for-
mulations.9,10,19e21 At the same time, adrenal function,
measured through morning plasma cortisol levels, remained
within the range of normality using both formulations.20 In
the present study, at the end of 24 weeks of treatment,
morning serum cortisol levels increased significantly versus
baseline with beclomethasone dipropionate/formoterol,
but remained substantially unchanged in the beclometha-
sone dipropionate CFC plus formoterol DPI and beclome-
thasone dipropionate CFC alone groups. The lack of cortisol
suppression observed with beclomethasone dipropionate/
formoterol confirms its favourable safety profile compared
with non-extra-fine formulations.
In conclusion, the present study demonstrates that
beclomethasone dipropionate/formoterol fixed combina-
tion, an extra-fine HFA pMDI formulation containing beclo-
methasone dipropionate in combination with formoterol,
offers at least similar efficacy and tolerability to beclo-
methasone dipropionate and formoterol delivered sepa-
rately via CFC-containing MDIs and DPIs, respectively, and
can be considered as a suitable therapeutic option for
patients with moderate to severe persistent asthma. In
addition, beclomethasone dipropionate/formoterol fixed
combination is the first inhaled corticosteroid/long-acting
b2 agonist single inhaler to show improved asthma control
compared with corresponding doses delivered via separate
inhalers. Further studies are needed to confirm this
preliminary finding and assess the mechanisms through
which this extra-fine inhaled corticosteroid/long-acting b2
agonist fixed combination may interfere with the patho-
physiological process in asthma; this will potentially have
consequent clinical implications.Conflict of interest
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